key: cord-0865080-d0iqpapl
authors: Hu, Hangchen; Wang, Qian; Su, Haixia; Shao, Qiang; Zhao, Wenfeng; Chen, Guofeng; Li, Minjun; Xu, Yechun
title: Identification of C270 as a novel site for allosteric modulators of SARS-CoV-2 papain-like protease
date: 2022-03-31
journal: bioRxiv
DOI: 10.1101/2022.03.30.486313
sha: 70031aafa3b5cb66f49288a617a0322141db2170
doc_id: 865080
cord_uid: d0iqpapl

The papain-like protease (PLpro) in coronavirus is one of key cysteine proteases responsible for the proteolytic processing of viral polyproteins, and plays an important role in dysregulation of host immune response. PLpro is a promising therapeutic target with a major challenge in inhibitor design due to the restricted S1/S2 sites for two consecutive glycine of substrates. Here we reported the discovery of two activators of the SARS-CoV-2 PLpro from a biochemical screening, and the identification of the unique residue, C270, as an allosteric and covalent regulation site for the activators. This site was also specifically modified by glutathione oxidized, resulting in the S-glutathionylation and activation of the protease. Furthermore, one compound was found to allosterically inhibit the protease by covalent binding to this crucial site. Together, these results elucidated an unrevealed molecular mechanism for allosteric modulation of the protease’s activity, and provided a new strategy for discovery of allosteric inhibitors of the SARS-CoV-2 PLpro.

Coronaviruses (CoVs) are highly diverse, enveloped, positive-sense, singlestranded RNA viruses, which are responsible for a wide range of diseases in animals as well as humans [1] [2] . The COVID-19 pandemic is caused by a new human CoV, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that appears to be more readily transmitted from human to human [3] [4] . Besides SARS-CoV-2, human infections with zoonotic CoVs including SARS in 2003 and Middle East respiratory syndrome (MERS) in 2012 caused severe respiratory diseases with high morbidity and mortality, posing a significant threat to public health across the world [5] [6] . SARS-CoV-2 was 96% identical at the whole-genome level to a bat coronavirus and shares 79.6% sequence identity to SARS-CoV [7] . The ongoing pandemic has caused unbearable number of infections and deaths worldwide which are still increasing, rendering it the most horrible pandemic since the 1918 Spanish flu [8] . It also marks the third introduction of a highly pathogenic CoV into the human population in the 21th century [9] .

CoVs share key genomic elements that provide promising therapeutic targets [10] .

A chymotrypsin-like cysteine protease, also called 3C-like protease (3CL pro ) or main protease (M pro ) [11] , together with a papain-like protease (PL pro ) [12] , is required to process two viral polyproteins into mature nonstructural proteins which are essential for viral transcription and replication. Besides, PL pro also recognizes and cleaves the C-terminal LxGG sequence of ubiquitin (Ub) and ubiquitin-like proteins (UbL) such as interferonstimulated gene product 15, acting as a deubiquitinase (DUB) to remove Ub or UbL from host proteins [13] [14] [15] [16] [17] . Antiviral immunity includes broad posttranslational modification by Ub and UbL which regulate host protein cellular localization and stability. The DUB activity of PL pro is supposed to cause dysregulation of host immune response against viral infection [18] [19] [20] [21] [22] . Thus, targeting PL pro is an attractive strategy to both inhibit viral replication and prevent disruption of the host immune response against viral infection.

Significant progress has been made in development of inhibitors targeting the SARS-CoV-2 3CL pro [23] [24] [25] [26] [27] . Discovery of PF-00835231 as a covalent active-site-directed inhibitor of the SARS-CoV 3CL pro in 2003 is conducive to rapidly develop inhibitors of the SARS-CoV-2 3CL pro [24] [25] [28] [29] . Currently, the most advanced inhibitor, nirmatrelvir (PF-07321332), in combination with ritonavir has been approved for the treatment of COVID-19 [28] . In comparison, PL pro of SARS-CoV and SARS-CoV-2 represents a more challenging target as very few potent inhibitors of this protease have been reported with validated in vitro as well as in vivo efficacy. A key issue from the standpoint of inhibitor design is the barrier derived from the restricted binding sites (S1/S2) for recognizing two consecutive glycine (P1/P2) in substrates of PL pro [30] [31] [32] .

Despite several high-throughput screening campaigns have been performed [13, 31, [33] [34] [35] [36] , GRL0617 which was originally identified as an inhibitor of the SARS-CoV PL pro [37] , remains one of the most potent PL pro inhibitors and the major starting point for optimization [17, 30, [38] [39] [40] [41] . Comprehensive understanding of structure-activity relationships of the protease and exploration of more ligand binding sites in addition to the catalytic (orthosteric) site is thus required for new potent inhibitor design.

In this work, we performed a high-throughput screening of compounds including FDA-approved drugs and candidates in clinical trials using an enzymatic assay. Though we embarked on our search for new inhibitors of the SARS-CoV-2 PL pro , we unexpectedly found two disulfide-containing activators which subsequently enabled us to identify a novel binding site on the SARS-CoV-2 PL pro and elucidated an unrevealed allosteric and covalent binding mechanism to regulate activity of the protease. Inspired by this discovery, an endogenous activator and the first allosteric inhibitor were also identified to covalently modify the protease through this site. These findings thereby gain the mechanistic insights into activity regulation of the SARS-CoV-2 PL pro and find a vital allosteric site for the development of novel inhibitors against SARS-CoV-2.

To measure the proteolytic activity of the recombinant SARS-CoV-2 PL pro , we carried out an enzymatic assay with a short fluorogeneic substrate, RLRGG-AMC, which is labelled with 7-amino-4-methylcoumarin (AMC) [42] . The hydrolysis of this substrate by the protease to release the AMC group results in a substantial enhancement of the fluorescent intensity. With this assay, FDA-approved drugs and candidate compounds in clinical trials (100 μM final concentration) were tested against the SARS-CoV-2 PL pro (50 nM final concentration) in order to screen inhibitors of the protease. Intriguingly, a number of activators which increase the proteolytic activity of the protease were resulted from the screening. Among them, two compounds both containing a disulfide bond, dimesna and pyritinol, led to more than 50% activation of the SARS-CoV-2 PL pro (Figure 1a) . Moreover, both compounds induced significant upregulation of the protease's activity in a dose-dependent manner ( Figure S1 ). We subsequently determined the values of half maximal effective concentration (EC50) and maximal effect (Emax) representing activation potency and efficacy, respectively, of the two activators. Dimesna, an uroprotective agent, activated the SARS-CoV-2 PL pro with an EC50 value of 1046 μM and an Emax value of 300.0% (Figure 1a and Figure S1 ). The other activator, pyritinol which is an analog of vitamin B6 for the treatment of cognitive disorders, activated the protease with an EC50 value of 18 μM and an Emax value of 226.5% (Figure 1a and Figure S1 ). The effect of these two compounds on Michaelis constant (Km) and maximum reaction rate (Vmax) of the fluorogeneic substrate hydrolyzed by the SARS-CoV-2 PL pro was also determined ( Table 1 ). Both activators rarely have an influence on Km but increased the Vmax values, indicating that the activators enhance the reaction rate rather than binding affinity of the substrate with the protease. Taken together, dimesna and pyritinol were found to be the allosteric activator of the SARS-CoV-2 PL pro for the first time. The result showed that two activators had comparable kinact values, which might be ascribed to the same reaction group, the disulfide bond. However, pyritinol had a much lower Ka value than that of dimesna, which suggests more noncovalent interactions formed between pyritinol and the protease. Therefore, dimesna and pyritinol are two covalent activators of the SARS-CoV-2 PL pro with the same reaction group but different amount of noncovalent contacts.

Considering that compounds containing a disulfide bond can act as covalent probes to characterize cysteine at allosteric sites [43] [44] [45] [46] [47] [48] , we predicted that the activity modulation of the SARS-CoV-2 PL pro by dimesna and pyritinol might be resulted from the modification of cysteine residue(s) of the protease through an action of disulfide exchange. To test this prediction, four vulnerable cysteine on the surface of the protease, C155, C181, C270, and C284, were individually mutated to serine. The resulting variants of the recombinant SARS-CoV-2 PL pro C155S, C181S, C270S, and C284S, were expressed and purified for the proteolytic activity measurement without or with addition of the activator (Figure 1d ). It was revealed that the enzymatic activity of all the variants except C270S were upregulated by the two activators, demonstrating that C270 of the SARS-CoV-2 PL pro was the modification site for the activators. It has been reported that C270 has the lowest pKa among all the cysteine of the SARS-CoV-2 PL pro except for the catalytic cysteine (C111) [49] , which means that C270 has a high reactivity and tendency for covalent modification. Though the catalytic C111 has the highest reactivity, it is not easy to be modified by two activators as it is located inside the protease and still works for catalytic hydrolysis of the substrate. Consequently, the enzymatic activity examination of the protease with single mutation of several surface cysteine reveals that C270 was modified by the two activators and this led to the activity upregulation of the SARS-CoV-2 PL pro , which is consistent with our prediction. 

The confirmation that C270 was the modulate site for two disulfide-containing compounds to active the SARS-CoV-2 PL pro turned our attention to an endogenous molecule, GSSG, which also contains a disulfide bond and has potential to modify the protease in this manner. To support this speculation, GSSG was tested and showed to upregulate the protease activity as anticipated ( Figure 2a ). In addition, such activation was eliminated by the introduce of the C270S mutant (Figure 2a ), which confirmed that the activity regulation was achieved through the modification of C270. The effect of GSSG on the Km and Vmax values of the SARS-CoV-2 PL pro was investigated (Table 1) .

Similar to the two activators mentioned above, GSSG hardly had an influence on the Km but increased the Vmax value (25.2 vs. 14.9). GSSG was also found to exert the time- It is worth noting that the physiological concentration of total glutathione in cells ranges from 1 to 10 mM, while the ratio of reduced to oxidized glutathione (GSH/GSSG) varies depending on the different condition and organelle of cells [50] [51] . Accordingly, we tested different ratios of GSH/GSSG at 5 mM for a total concentration of glutathione.

The enzymatic activity of the wild-type SARS-CoV-2 PL pro was upregulated at each ratio while it wasn't changed for the C270S variant ( Figure 2d ). This result indicates that the proteolytic activity of SARS-CoV-2 PL pro could be modulated by GSH/GSSG under the cellular conditions. In this context, a PL-FlipGFP assay [31] was performed to determine the intracellular activity of wild-type SARS-CoV-2 PL pro and the C270S variant ( Figure S2 ). In this assay, a fluorogenic GFP containing a cleavage site The result showed that the GFP/mCherry ratio of the wild-type and the C270S variant were nearly the same (100% vs. 101.6%) when transfected with the same amount of plasmids (Figure 2e and Figure S3 ). However, at this condition, the expression level of C270S variant was much higher than that of the wild-type. Since the GFP/mCherry ratio implied that the amount of hydrolyzed product resulting from two cases was similar, the higher expression level of C270S variant over the wild-type reflected the lower activity of C270S variant over the wild-type of SARS-CoV-2 PL pro in cells. Nevertheless, this situation might also be caused by the insufficient substrates.

To exclude this possibility, the amount of plasmid expressing the C270S variant was reduced to achieve the expression level similar to that of the wild-type. Consequently, the GFP/mCherry ratio of the wild-type was significant higher than that of the C270S variant (100% vs. 62.5%), demonstrating that the more hydrolyzed products were produced by the wild-type when the amount of expressed protein for two proteases was similar (Figure 2e ). Taken together, these data revealed the higher activity of the wildtype over the C270S variant of SARS-CoV-2 PL pro in cells which contains millimolar glutathione with different ratios of GSH/GSSG. It is thereby speculated that the performance of the intracellular proteolytic activity of SARS-CoV-2 PL pro on the viral polyproteins might be activated by the endogenous glutathione. 

The Table 2 showed that all the mutants didn't have significant influence on the Km in comparison to the Km value of the wild-type enzyme. As for Vmax, the mutagenesis such as C270S, C270V and C270L didn't make a difference to the wild-type. The C270E mutant with the negative charge was originally designed to resemble the modification of C270 by dimesna, but its Vmax value is much less than the one resulted from the addition of dimesna (11.4 vs. 42.6) and is even less than that of the wild-type (11.4 vs. 14.9). Additionally, the Vmax values of C270M (21.6), C270F (26.0) and C270Y (26.5) mutants increased in comparison to that of the wild-type (14.9), which may be ascribed to relatively large and electron-rich side chains of methionine, phenylalanine and tyrosine. In contrast, C270H, C270K and C270R mutants which all contain a positive-charged side chain resulted in values of Vmax smaller than that of the wild-type (9.3, 6.0, 4.7 vs. 14.9), suggesting that those mutagenesis caused an inhibition effect on the protease. Together, these results revealed that the substitution of C270 with amino acids containing large side chains to mimic the modification of C270 by compounds would affect the enzymatic activity of the protease, although detailed explanations for these results remain to be determined. It manifests again that C270 is a crucial allosteric site to modulate the protease's activity, and suggests that the covalent modification by the positive-charged molecule may exhibit an inhibition effect on the protease. 

With the aid of all suggestions from the above results, bis It has been noted in Introduction that the discovery of PL pro inhibitor is hampered by the restricted S1/S2 site for the binding of the tandem glycine in substrates. Such a space restriction also prevents the covalently binding of ligand to the catalytic C111.

The discovery of C270 as an allosteric site thus provide an alternative route to inhibitor design. DMGA with single digit micromolar potency acts as a hit for further development of potent allosteric inhibitor.

In summary, we have investigated the activity modulation of the SARS-CoV-2 PL pro by three activators, one inhibitor and eleven single-point mutants which

consistently have an impact on the Vmax but not the Km of the protease by exerting the covalent modification on the surface C270, demonstrating the significance as well as feasibility of C270 working as an allosteric site for all the modulators. Noteworthy, the activators seen in the screening campaigns of inhibitors is ignored in general, while it is the fact that these activators frequently bind to an allosteric site which is potentially valuable for novel inhibitor design. The present study provides such a paradigm for the discovery of novel allosteric inhibitors of the SARS-CoV-2 PL pro by utilizing the serendipitously discovered activators to identify the allosteric binding site.

To investigate the sequence conservation of C270 among PL pro , we performed a sequence alignment of pp1ab from seven human CoVs ( Figure S4 ). It was revealed that C270 is unique to the SARS-CoV and SARS-CoV-2 PL pro , and instead valine was found in the other five CoVs' PL pro at the equivalent position. Considering that only C270 was targeted by GSSG to increase the activity of the protease, this unique residue might be associated with the severe consequences of SARS-CoV and SARS-CoV-2 infections to human beings. Additionally, the unique C270 of the SARS-CoV and SARS-CoV-2 PL pro provides the structural basis for discovery of selective allosteric modulators.

The pandemic of COVID-19 together with the epidemics of SARS and MERS has raised great awareness about the increasing infection risks of highly pathogenic CoVs, calling for a huge demand in discovery of anti-coronaviral drugs. PL pro is a highly conserved cysteine proteinase that is indispensable for coronavirus replication, providing an attractive but challenging target for developing broad-spectrum antiviral drugs. Herein, we find a novel allosteric inhibitor of the SARS-CoV-2 PL pro with a covalent action to C270 which is a previously unrecognized site for allosteric regulation of the protease's activity. The mechanism of action of such a new inhibitor and structural determinants associated with its binding uniquely suited for engaging the non-catalytic cysteine are significantly distinctive to known inhibitors which bind to the catalytic site of the SARS-CoV-2 PL pro . Rather unexpectedly, the discovery of this allosteric site is derived from the identification of two activators, dimesna and pyritinol, from a high-throughput screening. Moreover, this vital site is also covalently modified by GSSG, an endogenous activator, which may link to intracellular proteolytic activity of the SARS-CoV-2 or SARS-CoV PL pro . Our study thereby highlights a promising strategy for identification of the unrecognized allosteric modulation site based on the discovery of covalent probes and reveals an exquisite allosteric modulation mechanism for the protease, which offers a great opportunity for the development of new inhibitors of the SARS-CoV PL pro .

Identification 

The GenScript. The mutants used in this study were constructed by site mutation PCR and verified with sequencing.

The plasmids of SARS-CoV-2 PL pro and its variants for protein expression were 

The enzymatic assay of all compounds were performed using 96-well plates. The substrate used in the assay was the fluorogeneic peptide (RLRGG-AMC) [42] , which was synthesized by GenScript. Reactions were performed in a total volume of 120 μL, which contained the following components: 50 mM Tris pH7. 5 

The interaction of covalent compounds with the SARS-CoV-2 PL pro can be described in two steps: an initial reversible binding event (Ki for inhibitors, Ka + Ki or Ka)) using GraphPad Prism.

This assay was designed stemming from previous reports [31, 52] In detail, a FlipGFP in which the 10th and 11th β-strands were separated from the rest of the GFP β-barrel (βstrands 1-9) were used. The 10th β-strand, the coiled-coil E5, the 11th β-strand, the cleavage sequence (LRGGAPTK) by the SARS-CoV-2 PL pro , and the coiled-coil K5

were linked in order ( Figure S2 ). In the absence of the SARS-CoV-2 PL pro , the FlipGFP is inactive, as the 10th and 11th β-strands were restrained due to the presence of heterodimerized coiled-coil E5/K5 and unable to associate with the rest of GFP β-barrel.

Upon the cleavage by the protease, the 10th or 11th β-strands then flips to associate with β-strands 1-9, leading to restoration of the integrated GFP for green fluorescence detection. Meanwhile, a red fluorescent protein mCherry was included via a "selfcleaving" 2A peptide to act as an internal control, and the ratio of green over red fluorescent signal (GFP/mCherry) represents the amount of products generated by the protease hydrolysis in cells. Figure S4 . Multiple alignment of seven human COVs' pp1ab protein sequences generated by Clustal Omega program [53] (https://www.uniprot.org/align/). Red triangle marks the equivalent position of C270 on SARS-CoV-2 PL pro . Only the window of the amino acids nearby C270 was shown for clarity reasons.

Coronaviruses -drug discovery and therapeutic options

SARS and MERS: recent insights into emerging coronaviruses

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Early transmission dynamics in Wuhan, China, of novel coronavirusinfected pneumonia

Origin and evolution of pathogenic coronaviruses

Epidemiology, genetic recombination, and pathogenesis of coronaviruses

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Intensive care management of patients with COVID-19: a practical approach

Mechanisms of SARS-CoV-2 transmission and pathogenesis

Coronavirus biology and replication: implications for SARS-CoV-2

What coronavirus 3C-like protease tells us: From structure, substrate selectivity

Nsp3 of coronaviruses: Structures and functions of a large multidomain protein

Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2

Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity

Structural basis for the ubiquitin-linkage specificity and deISGylating activity of SARS-CoV papain-like protease

The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity

Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease

SARS coronavirus papain-like protease inhibits the type I interferon signaling pathway through interaction with the STING-TRAF3-TBK1 complex

Severe acute respiratory syndrome coronavirus papainlike protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappa B signaling

ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity

Altered ISGylation drives aberrant macrophage-dependent immune responses during SARS-CoV-2 infection

An inflammatory cytokine signature predicts COVID-19 severity and survival

SARS-CoV-2 M(pro) inhibitors with antiviral activity in a transgenic mouse model

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients

Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease

An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19

Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19

Design of SARS-CoV-2 PLpro inhibitors for COVID-19 antiviral therapy leveraging binding cooperativity

Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and a FlipGFP-based reporter assay

Drug development and medicinal chemistry efforts toward SARS-coronavirus and Covid-19 therapeutics

Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design

Drug repurposing for the SARS-CoV-2 papain-like protease

Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2

High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors

A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors

The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery

Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2

Crystal structure of SARS-CoV-2 papain-like protease

Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease

Turning a protein kinase on or off from a single allosteric site via disulfide trapping

The design of covalent allosteric drugs

Increase of enzyme activity through specific covalent modification with fragments

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Searching for new allosteric sites in enzymes

Tethering: fragment-based drug discovery

Assessment of proton-coupled conformational dynamics of SARS and MERS coronavirus papain-like proteases: Implication for designing broad-spectrum antiviral inhibitors

Oxidized redox state of glutathione in the endoplasmic reticulum

Intracellular glutathione pools are heterogeneously concentrated

After 48 hours, the supernatant was removed and 200 μL lysis buffer (100 mM Tris pH7.5, 100 mM NaCl, 1 mM EDTA, 1% Triton X-100) was added. After incubation for 5 min at 4 °C, 120 μL cell lysate was transferred to a 96-well plate and the fluorescent signal of GFP (excitation: 475 nm, emission: 505 nm) and mCherry (excitation: 580 nm, emission: 610 nm) were measured. The amount of hydrolyzed product in cells was calculated based on the ratio of GFP/mCherry fluorescent signal

S-glutathionylation of the SARS-CoV-2 PL pro Concentrated protease (the wild-type or C270S variant of SARS-CoV-2 PL pro ) was

After that, the samples were divided into two parts. Under the reduced condition, samples were additionally added with 1% β-mercaptoethanol

Membranes were washed with TBST (50 mM Tris pH7.5, 150 mM NaCl, 0.1% Tween 20) and blocked with 5% bovine serum albumin (BSA) in TBST for 1 h at 25 °C. Membranes were first incubated with the primary antibody

5% BSA TBST for 16 h at 4 °C, washed with TBST three times, then incubated with the secondary antibody (HRP-labeled Goat Anti-Mouse

This work was supported by the National Natural Science Foundation of China